Amphotericin B: A class review

Formulary

Volumn 33, Issue 5, 1998, Pages 424-447

  Singh, Rubina M ^a   Perdue, Beulah E ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; DIGITALIS GLYCOSIDE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; PENTAMIDINE; TACROLIMUS; THIAZIDE DIURETIC AGENT; ZIDOVUDINE;

ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOCYTE TRANSFUSION; LIVER TRANSPLANTATION; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; REVIEW;

EID: 0032442998     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Micromedex Computerized Clinical Information System. Reynolds JEF, ed. Denver: Micromedex, 1997.
2. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28 (Suppl B):83-91.
3. Lister J: Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: The North American experience. Eur J Haematol 1996;56(Suppl 57):18-23.
4. Dix SP, Wingard JR. Amphotericin B lipid complex: Review of safety, pharmacokinetics and efficacy. Drugs of Today 1996;32(Suppl G):19-25.
5. AmBisome (amphotericin B liposome for injection) package insert. Fujisawa USA, Inc, Deerfield, IL, August 1997.
6. Drug Facts and Comparisons. St. Louis: Facts and Comparisons, March 1997:356-357e.
7. Szoka FC, Tang M. Amphotericin B formulated in liposomes and lipid-based systems: A review. J Liposomal Res 1993;3:363-75.
8. Heinemann V, Kahny B, Debus A, et al. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994;14(Suppl 5):S8-S9.
9. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6.
10. Abelcet (amphotericin B lipid complex injection) package insert. The Liposome Co, Inc, Princeton, NJ, October 1996.
11. Amphotec (amphotericin B cholesteryl sulfate complex for injection) package insert. Sequus Pharmaceuticals, Inc, Menlo Park, CA, October 1996.
12. Fromtling RA. Experimental and clinical pharmacokinetics of amphotericin B lipid complex. Drugs of Today 1996;32(Suppl G):9-17.
13. Isada CM, Kasten BL, Goldman MP, et al, eds. Infectious Diseases Handbook. 2nd ed. Hudson, OH: Lexi-Comp, Inc, 1997-98.
14. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(Suppl B):73-82.
15. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.